Nintedanib is a selective small-molecule inhibitor of FGFR, vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) that has recently been approved for second-line treatment after chemotherapy failure in advanced lung adenocarcinoma [15, 16]. The gene discussed is PDGFRB; the disease is lung adenocarcinoma.